Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1618 publications

Carfilzomib triggers cardiotoxicity by suppressing SENP1-mediated deSUMOylation of DDX17.

Carfilzomib triggers cardiotoxicity by suppressing SENP1-mediated deSUMOylation of DDX17.

Journal: Acta biochimica et biophysica Sinica
Published: October 11, 2025

Definition and Classification of Pulmonary Hypertension

Definition and Classification of Pulmonary Hypertension

Journal: Pneumologie (Stuttgart, Germany)
Published: October 06, 2025

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

Journal: Leukemia & lymphoma
Published: October 03, 2025

The Rarest Subtype of Plasma Cell Dyscrasia: IgE Multiple Myeloma.

The Rarest Subtype of Plasma Cell Dyscrasia: IgE Multiple Myeloma.

Journal: Cureus
Published: September 01, 2025

Recombinant proteasome provides new avenues for anti-malarial drug development.

Recombinant proteasome provides new avenues for anti-malarial drug development.

Journal: bioRxiv : the preprint server for biology
Published: August 20, 2025

A recombinant expression system for the Plasmodium falciparum proteasome enables structural analysis of its assembly and the design of selective inhibitors.

A recombinant expression system for the Plasmodium falciparum proteasome enables structural analysis of its assembly and the design of selective inhibitors.

Journal: bioRxiv : the preprint server for biology
Published: August 20, 2025

Dexamethasone desensitization in type III hypersensitivity reaction and multiple myeloma.

Dexamethasone desensitization in type III hypersensitivity reaction and multiple myeloma.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: August 05, 2025

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

Journal: EJHaem
Published: August 01, 2025

Carfilzomib-Associated Thrombotic Microangiopathy in a Multiple Myeloma Patient: Complement Genetic Alterations Impact and Eculizumab Therapy.

Carfilzomib-Associated Thrombotic Microangiopathy in a Multiple Myeloma Patient: Complement Genetic Alterations Impact and Eculizumab Therapy.

Journal: Cureus
Published: July 31, 2025

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

Journal: Cancers
Published: July 31, 2025

Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database.

Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database.

Journal: Hematology (Amsterdam, Netherlands)
Published: July 22, 2025

Highlights from the European Hematology Association Congress 2025.

Highlights from the European Hematology Association Congress 2025.

Journal: Acta haematologica
Published: July 21, 2025
Showing 1-12 of 1,618

Last Updated: 10/31/2025